DEFA
14A
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to section 14(a) of the Securities and Exchange Act of 1934 (Amendment No. )
Filed
by the Registrant [X]
Filed
by a Party other than the Registrant [ ]
Check
the appropriate box:
[
] Preliminary Proxy Statement
[
] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
[
] Definitive Proxy Statement
[X]
Definitive Additional Materials
[
] Soliciting Material Pursuant to §240.14a-12
Fonar
Corporation
………………………………………………………………………………………………
(Name
of Registrant as Specified In Its Charter)
………………………………………………………………………………………………
(Name
of Person(s) Filing Proxy Statement if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
[X]
No fee required
[
] Fee computed on table below per Exchange Act Rules 14-6(i) (1) and 0-11.
1)
Title of each class of securities to which transaction applies:
N/A
………………………………………………………………….
2)
Aggregate number of securities to which transaction applies:
N/A
………………………………………………………………….
3)
Per unit price or other underlying value of transaction computed pursuant to
Exchange
Act Rule 0-11 (Set forth the amount of which the filing fee is
calculated
and state how it was determined:
N/A
…………………………………………………………………..
4)
Proposed maximum aggregate value of transaction:
N/A
………………………………………………………………………
5)
Total fee paid:
N/A
……………………………………………………………………….
[
] Fee paid previously with preliminary materials.
[
] Check box if any part of the fee is offset as provided by Exchange Act Rule 240.0-11 (a)(2) and identify the filing for which
the offsetting fee was paid previously. Identify the previous filing by registration number, or the Form or Schedule and the date
of its filing.
1)
Amount Previously Paid:
………………………………………
2)
Form, Schedule or Registration Statement No.:
……………………………………….
3)
Filing Party:
………………………………………..
4)
Date Filed:
………………………………………..
This
press release, issued on April 10, 2019, contains the revised version of the FONAR CHAIRMAN’S LETTER TO SHAREHOLDERS contained
in Fonar Corporation’s annual report filed with its proxy statement on April 5, 2019.
NEWS
|
|
FONAR Corporation
|
For Immediate Release
|
|
The Inventor of MR Scanning™
|
Contact: Daniel Culver
|
|
An ISO 9001 Company
|
Director of Communications
|
|
Melville, New York 11747
|
E-mail:
investor@fonar.com
|
|
Phone: (631) 694-2929
|
www.fonar.com
|
|
Fax: (631) 390-1772
|
FONAR Announces
Annual Meeting and Shareholder Letter
MELVILLE, NEW
YORK, April 10, 2019 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported today it is holding its annual
shareholder meeting on May 20, 2019, in Wilmington, DE. The proxy statement, filed on Friday, April 5, 2019, contains the annual
FONAR CHAIRMAN’S LETTER TO SHAREHOLDERS.
FONAR
CHAIRMAN’S LETTER TO SHAREHOLDERS
May
2019
Dear
Shareholders:
I am pleased to report
that as of December 31, 2018, FONAR posted 35 consecutive quarters of positive net income and positive income from operations.
Fiscal Year Ended June 30,
|
|
Total FONAR Revenue
|
|
Total FONAR Net (Loss) Income
|
|
Diluted Net (Loss) Income Per Common Share
|
|
2010
|
|
|
$
|
31,815,555
|
|
|
($
|
3,012,742
|
)
|
|
($
|
0.61
|
)
|
|
2011
|
|
|
$
|
33,136,395
|
|
|
$
|
3,309,019
|
|
|
$
|
0.55
|
|
|
2012
|
|
|
$
|
39,444,419
|
|
|
$
|
6,875,073
|
|
|
$
|
0.91
|
|
|
2013
|
|
|
$
|
49,141,814
|
|
|
$
|
10,256,362
|
|
|
$
|
1.34
|
|
|
2014
|
|
|
$
|
68,505,477
|
|
|
$
|
13,396,769
|
|
|
$
|
1.58
|
|
|
2015
|
|
|
$
|
69,050,996
|
|
|
$
|
15,430,383
|
|
|
$
|
1.95
|
|
|
2016
|
|
|
$
|
73,368,210
|
|
|
$
|
18,795,517
|
|
|
$
|
2.38
|
|
|
2017
|
|
|
$
|
78,036,586
|
|
|
$
|
23,678,798
|
|
|
$
|
2.92
|
|
|
2018
|
|
|
$
|
81,515,994
|
|
|
$
|
25,452,185
|
|
|
$
|
3.10
|
|
FONAR’s
primary source of income and growth has been attributable to Health Management Company of America (HMCA), the company’s
diagnostic imaging management subsidiary. In calendar 2009, the facilities under management by HMCA completed 29,000 MRI scans.
Since then, my son Timothy (president and CEO of FONAR) and his hand-picked management have grown HMCA significantly. At present,
HMCA manages diagnostic imaging centers that in 2018 completed 180,000 MRI scans, compared to 170,000 in 2017.
About HMCA
In response to the
financial uncertainties caused by erratic MRI equipment sales in the 1990’s, FONAR sought a steady and reliable source of
revenue. At that point, not only was FONAR, as the inventor of MR scanning, the master of MRI technology, but FONAR, having worked
with its customers for nearly 20 years, had also become very familiar with the day-to-day management of independent MRI scanning
centers. Ideally positioned to expand into the MRI practice management business, FONAR formed the HMCA subsidiary in 1997. Since
then, HMCA has become the leading source of revenue and profit.
HMCA’s continuing
success is fundamentally attributable to the ever-growing appeal of FONAR MRI technology among patients and physicians. Patients
strongly prefer the FONAR Multi-Position™ UPRIGHT® MRI, also known as the Stand-Up® MRI, for its comfort and openness,
unlike the more conventional “tunnel” MRIs. Physicians are drawn to the UPRIGHT® MRI as well, for two reasons:
They can accommodate their patients’ preferences without compromising on diagnostic image quality, and for the many instances
where the anatomy of interest needs to be viewed in a weight-bearing position, such as the lower back and cervical spine with the
patient either standing or sitting, the UPRIGHT® is the only MRI that can do it. But outstanding technology is no guarantee
of success. It has to be properly marketed, and the patients and their physicians have to be pleased with the service they receive
at the scanning centers. Accordingly, marketing and service to both patients and referring doctors are top priorities at HMCA-managed
centers.
Regarding the future,
HMCA continues to conduct demographic studies in search of de novo locations and/or acquisition opportunities in New York and Florida
that are compatible with our business plan and would add quickly and significantly to net revenues and profit.
About FONAR
FONAR, The Inventor
of MR Scanning™, located in Melville, NY, was incorporated in 1978 and is the first, oldest and most experienced MRI company
in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. The Company, which has installed
over 400 MRIs all over the world, continues to manufacture, sell, service and upgrade FONAR scanners.
FONAR's
signature product is its fully patented FONAR UPRIGHT® Multi-Position™ MRI (also known as the Stand-Up® MRI), the
only whole-body MRI that can perform Position™ imaging (pMRI™), which means patients can be scanned in numerous weight-bearing
positions, i.e. standing, sitting, in flexion and extension, as well as in the conventional lie-down position. The FONAR UPRIGHT®
MRI often detects patient problems that other MRI scanners cannot because they are “lie-down-only”, or "weightless-only"
scanners. Weight-bearing MRI enables more complete diagnoses in comparison to “weightless” MRIs. In fact, the FONAR
UPRIGHT® Multi-Position™ MRI has detected problems that were underestimated or missed entirely on “weightless-only”
MRI scanners, particularly scans of the spine. This is very important because most MRI scans performed are of the spine. With the
UPRIGHT® MRI’s power to “see it all,” the benefits of this unique scanner continue to gain traction in the
medical community because the UPRIGHT® provides referring physicians the means to achieve better outcomes for their patients.
There
is another very important feature of the UPRIGHT® MRI. It is the Patient-Friendly™ MRI, a claim strongly supported by
the near-zero claustrophobic rejection rate by patients. In fact, approximately 85% of patients are scanned sitting while watching
TV. The unique diagnostic benefits of the FONAR UPRIGHT® Multi-Position™ MRI, along with its enormous popularity among
patients, contribute significantly to the success enjoyed by FONAR users everywhere.
MRI
is “The Single Most Important Diagnostic Discovery in the History of All of Medicine” - Professor Donlin Long, M.D.,
former Chairman of Neurosurgery, Johns Hopkins University
Professor Long
made this statement on November 10, 2018, when I was awarded the Excellence in Medicine Medal of Honor from the Chiari & Syringomyelia
Foundation at Brooks’s in London, England. He was joined by Fraser Henderson, M.D., a neurosurgeon and member of the steering
committee for the Chiari & Syringomyelia Foundation, who said, “Raymond Damadian revolutionized medicine with the discovery
and development of MRI.”
The award citation
included: “In 1970, Raymond Damadian made the discovery that is the basis for MR scanning - that there is a marked difference
in relaxation times between normal and abnormal tissues of the same type, as well as between different types of normal tissues.
This seminal discovery, which remains the basis for the making of every MRI image ever produced, is the foundation of the MRI industry.”
While this award
was very gratifying to me personally, I gratefully acknowledge the support and contributions of family, friends, FONAR employees
and FONAR stockholders for their support in creating an industry that has helped millions all over the world.
FONAR Technology
Credited
A peer-reviewed research
chapter found on-line at IntechOpen.com states that the “FONAR upright weight-bearing MRI has been shown to be most sensitive
in detecting cerebellar tonsillar ectopia since the weight-bearing posture presents the cerebellar tonsils further distended into
the foramen magnum.” Later in the chapter, it states, “Upright Cine MRI of the cranio-cervical junction demonstrates
CSF flow dynamics.” These give significant credit to the FONAR UPRIGHT® Multi-Position™ MRI.
Essentially, this
chapter reports on the latest FONAR UPRIGHT® (fully weight-loaded) evidence regarding the craniocervical junction syndrome
(CCS). My own research, using the FONAR UPRIGHT® Multi-Position™ MRI, indicates that the CCS is a major cause of many
neurodegenerative diseases. Continued understanding of the CCS may plausibly have a significant impact on the genesis and treatments
of the many neurodegenerative diseases that plague mankind. These include Multiple Sclerosis, Amyotrophic Lateral Sclerosis (Lou
Gehrig’s Disease), Alzheimer’s, Parkinson’s and additionally the non-neurodegenerative diseases Childhood Autism
and birth injury Cerebral Palsy.
Ongoing Research
FONAR continues its
work on visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF),
which circulates from the brain to the sacrum of the vertebral column at the rate of 32 quarts per day. This imaging and quantifying
of the dynamics of this vital life-sustaining physiology of the body’s neurologic system has been made possible first by
FONAR’s introduction of the MRI and now by this latest works-in-progress method for quantifying CSF flow in all the normal
positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among
those who will benefit from this new understanding.
Conclusion
I believe that
the combination of FONAR’s unique technology and the ongoing success of our diagnostic imaging management subsidiary, HMCA,
will keep FONAR on the path of steady growth and profitability for years to come.
As always, I remain
grateful to our stockholders, customers and employees for their loyal support.
Sincerely,
Raymond V.
Damadian
Chairman
A
bout
FONAR
FONAR, The
Inventor
of MR Scanning
™, is located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced
MRI company in the industry. FONAR introduced the world’s first commercial MRI in 1980, and went public in 1981.
The
Company’s two industry segments are: development, manufacturing and servicing of the
FONAR UPRIGHT® Multi-Position™
MRI, aka Stand-Up® MRI,
and
management of 26 MRI centers through its subsidiary,
Health Management Company of America (HMCA).
FONAR’s
signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the Stand-Up® MRI), the only whole-body
MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing,
sitting, in flexion, extension, and spinal rotation, as well as the conventional lie-down only position. The FONAR
UPRIGHT®
MRI
often detects patient problems that other MRI scanners cannot because they are lie-down only and ”weightless”
only scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer
states, “If the patient is claustrophobic in this scanner, they’ll be claustrophobic in my parking lot.” Approximately
85% of patients are scanned sitting while watching TV.
FONAR has new
works-in-progress
technology for visualizing and quantifying the cerebral hydraulics of the central
nervous system, the flow of cerebrospinal fluid (CSF),
which circulates throughout the brain and vertebral column at the
rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s
neurologic system has been made possible first by FONAR’s introduction of the MRI and now by this latest works-in-progress
method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients
with whiplash or other neck injuries are among those who will benefit from this new understanding.
FONAR’s
substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity
sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring
the Upright cerebral hydraulics of the central nervous system. FONAR’s UPRIGHT® Multi-Position™ MRI is the only
scanner licensed under these patents.
UPRIGHT®
and
STAND-UP®
are registered trademarks and
The Inventor of
MR Scanning™
, Full Range of Motion™,
Multi-Position™
, Upright Radiology™,
The Proof is in the Picture™
, True Flow™,
pMRI™
,
Spondylography™,
Dynamic™
, Spondylometry™,
CSP™
,
and Landscape™, are trademarks of FONAR Corporation.
This release may include forward-looking
statements from the company that may or may not materialize. Additional information on factors that could potentially affect the
company's financial results may be found in the company's filings with the Securities and Exchange Commission.
Fonar (NASDAQ:FONR)
Historical Stock Chart
From Apr 2024 to May 2024
Fonar (NASDAQ:FONR)
Historical Stock Chart
From May 2023 to May 2024